Anbio Biotechnology (NNNN) Liabilities and Shareholders Equity (2023 - 2025)

Anbio Biotechnology has reported Liabilities and Shareholders Equity for 3 years, with the latest figure at $30.2 million in Q4 2025.

• On a quarterly basis, Liabilities and Shareholders Equity rose 59.83% year-over-year to $30.2 million in Q4 2025; TTM through Dec 2025 was $92.7 million, a N/A change from a year earlier, with the FY2025 full-year figure at $30.2 million, up 59.83% from the prior year.
• Liabilities and Shareholders Equity was $30.2 million for Q4 2025 at Anbio Biotechnology, up from $27.7 million in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $30.2 million in Q4 2025, with the low at $15.8 million in Q4 2023.
• Average Liabilities and Shareholders Equity over 3 years is $23.2 million, with a median of $23.3 million recorded in 2024.
• The sharpest annual moves came in 2024 and 2025: Liabilities and Shareholders Equity grew 19.67% in 2024, then jumped 59.83% in 2025.
• Over 3 years, Liabilities and Shareholders Equity stood at $15.8 million in 2023, then climbed by 19.67% to $18.9 million in 2024, then surged by 59.83% to $30.2 million in 2025.
• The last three Liabilities and Shareholders Equity figures came in at $30.2 million (Q4 2025), $27.7 million (Q2 2025), and $18.9 million (Q4 2024), per Business Quant data.